Straits Times Index
3,110.73 +36.47 (+1.19%) Nikkei
32,307.86 -550.45 (-1.68%) Hang Seng
16,334.37 -11.52 (-0.07%) FTSE 100
7,554.47 +40.75 (+0.54%) Bitcoin USD
43,819.68 +303.42 (+0.70%) CMC Crypto 200
914.81 +18.10 (+2.02%)
ACADIA Pharmaceuticals Inc. (0A4W.L)
| Previous close | 21.59 |
| Open | 21.73 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 20.88 - 21.76 |
| 52-week range | 15.18 - 33.96 |
| Volume | |
| Avg. volume | 406 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.33 |
| Earnings date | 26 Feb 2024 - 01 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireAcadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome
SAN DIEGO, November 30, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of the Phase 3 COMPASS PWS study evaluating the efficacy and safety of carbetocin nasal spray (ACP-101) for the treatment of hyperphagia in Prader-Willi syndrome (PWS). PWS is a rare, neurobehavioral genetic disorder that is estimated to affect 8,000 to 10,000 patients in the United States.1-4 The most common symptom is hyperphagia, which is an unrelenting lack of satiety. Other defining featu
Business WireAcadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
SAN DIEGO, November 27, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of a Phase 2 study evaluating the efficacy and safety of ACP-204 for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). Of the more than 6.5 million people in the United States living with Alzheimer’s disease (AD), approximately 30% will experience psychosis, commonly consisting of hallucinations and delusions.1-3
ZacksZacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals
Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals are part of the Zacks Industry Outlook article.
